Piramal Pharma appoints Amit Soni as independent director

Piramal Pharma Limited announced the appointment of Amit Soni as a non-executive, independent director, effective February 9, 2026. The appointment, based on the Nomination and Remuneration Committee's recommendation, is for a five-year term and is subject to shareholder approval. Mr. Soni is not related to any existing directors and has been confirmed not to be debarred from holding a director's office by any regulatory authority.

Mr. Soni brings extensive experience, having served as a partner at CVC Capital since 2017, where he led the deployment of $980m across five deals in India, including notable investments like Gujarat Titans and a majority stake in Healthcare Global. Prior to CVC, he spent nine years with General Atlantic, leading investments in technology, financial services, and healthcare in India, with key engagements including Bill Desk, CitiusTech, IndusInd Bank, MedExpress, and Red Ventures.

His professional background also includes roles at 3i, the Bill & Melinda Gates Foundation, and McKinsey & Company. Mr. Soni holds an MBA from The Wharton School and a bachelor of technology degree in Electrical Engineering from IIT Delhi. His profile suggests a strong track record in scaling businesses and partnering with founders and management teams.